Investor Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.  

The Company is evaluating its investigational drug candidate EVO100 for the prevention of chlamydia and gonorrhea in women in a pivotal Phase 3 clinical trial, EVOGUARD. Top-line results are expected in mid-2022 and assuming positive results Evofem plans to file an sNDA in the fourth quarter of 2022.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.